Lots of useless chatter overtop of my post/worth a repostIt has been a long time of silence, with anything related to upcoming phase 3. That being either the pancreatic or MBc Cancers.
In the background the science, AKA on- going trial(s) & various survivable time lines, ..have without anything that can be done, just keep on according.
As I mentioned previously, it is a troublesome paradox. The longer the patients live ( great news), the longer it takes to publicize any additional trial data.( troubling for those looking for news)
Overall survival, " results", are based on the continued lives of the patients in the trial.
Nothing to do with mangement, locations, advisors & certainly not the trading S.P.
The long awaited O.S. results are 100% based on patients health, recovery & the mortality of the cancer.
while bad for news flow, longer is better.
The most recent FDA type " C " meeting?
Some find it a requirement to point out the maximum time for an FDA response.
Considering they all ready have in- place fast track designation. The longest time period is possible. However not likely.
depends in the complexity of the questions & expected answers.
The meetings of that calibre usually have predetermined outcomes, Meaning a formality to validate prior discussions.
beyond that ( as we can all banter on this date or that date). a quick read if the N.R. Says quite clearly a significant briefing has been put together with the assistance of clinical collaborations & partners. & the meeting is requested for this quarter.
Meaning , soon.
Most importantly ? As was mentioned how to finance the trail,
Oncolytics biotech, has said from day one. The phase 3 & marketing of Pelareorep will require a business partner.
Since the briefing was drafted with the guidance of outside partners/ collaborators, common sense woukd be. Once a plain in place then a proper $$ can be attributed to the costs and outcomes of that plan.
it is very possible the phase 3 environment won't start until Q3/4, of this year.
However, there will be an announced plan & partnership, long before the enrolment.
Next shoe to drop is the PanCan/ Pancreatic cancer phase 3 trial information.
Will the $$$ source be a surprise as Notable suggested?
First , I agree 100%, this meeting announcement is very good news & can lead to a modified phase 3 trial.
Second , funding a surprise?
i have stated previously, one of 3 obvious options, plus some we can't even think of.
1. A complete buyout of the company.
2. a licensing agreement with upfront $$ and biobucks based on measurable achievements.
3. A spin- off company, with ONC & the partner being co- owners.
Alternatives?
combinations of #1,2 & #3.
Other business deals?
Majority of the 6 analysts covering onc(y), have predicted a partnership announcement before the end of this year.
Using Nitables words " a surprise"
Just me, at this juncture nothing would surprise me.
The S.P. Is trading a fraction of where it should be.
Looking a bit further out, it is quite possible to get Pela to market under accelerated approval for both MBc and Pancreatic cancer.
THAT makes Onc a multi billion $$ company.
Not there yet. Obviously, however as I started.
the MBc O.S, results are taking a long time. That is great news!
not good for those in a rush, to make your quick in & out trade.
Let's see what comes next.
At least we know why the recent premarket activity.
Those who understand are buying. The others, bashing & blaming. ...it's taking too long...
BTW side note, a comment was made regarding my lack of posts on another site.
i have tried, but those moderating delete anything I post with a positive point of view
No doubt same happening to others.
leaving that site exactly what the zfUDsters wanted a messy pile of goo.
suggesting " your" posts are deleted on this site? Not possible.
only the author can delete his/ her own posts.
exception to that, if you use outside links or inappropriate language.
regards
wishing everyone a safe & healthy week.